{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:26:17Z","timestamp":1778657177083,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.vaccine.2018.11.073","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T08:28:19Z","timestamp":1549960099000},"page":"1710-1719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents"],"prefix":"10.1016","volume":"37","author":[{"given":"Timo","family":"Vesikari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Munson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.11.073_b0005","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2018.11.073_b0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/INF.0000000000000282","article-title":"The clinical features and long-term sequelae of invasive meningococcal disease in children","volume":"33","author":"Stein-Zamir","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2018.11.073_b0020","unstructured":"European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 \u2013 Invasive meningococcal disease. Available at: http:\/\/ecdc.europa.eu\/en\/healthtopics\/meningococcal\/Pages\/Annual-epidemiological-report-2016.aspx. Accessed April 24, 2017."},{"key":"10.1016\/j.vaccine.2018.11.073_b0025","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","article-title":"Global incidence of serogroup B invasive meningococcal disease: a systematic review","volume":"15","author":"Sridhar","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.073_b0030","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0040","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.073_b0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.11.073_b0050","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.11.073_b0055","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u2265 10 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.073_b0060","unstructured":"European Medicines Agency. EPAR summary for the public: Trumenba. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004051\/WC500228998.pdf. Accessed October 23, 2017."},{"key":"10.1016\/j.vaccine.2018.11.073_b0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine \u2014 Advisory Committee on Immunization Practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.073_b0070","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.073_b0075","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","article-title":"Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial","volume":"34","author":"Baxter","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0080","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0085","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0090","doi-asserted-by":"crossref","first-page":"e20162193","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.11.073_b0095","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines \u2013 Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.11.073_b0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jpids\/piv039","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2018.11.073_b0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","article-title":"The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease","volume":"11","author":"Zlotnick","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.11.073_b0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jpids\/piv064","article-title":"Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2018.11.073_b0115","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine","volume":"35","author":"Senders","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0120","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal B vaccine in adolescents and young adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.11.073_b0125","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.11.073_b0130","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"issue":"suppl 2","key":"10.1016\/j.vaccine.2018.11.073_b0135","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.11.073_b0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(16)30314-0","article-title":"Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Marshall","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.11.073_b0145","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.11.073_b0150","doi-asserted-by":"crossref","first-page":"E1276","DOI":"10.1503\/cmaj.161288","article-title":"Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules","volume":"189","author":"Sadarangani","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2018.11.073_b0155","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/INF.0000000000001124","volume":"35","author":"Muse","year":"2016","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T15:38:30Z","timestamp":1565192310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18316360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0264410X18316360"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}